Abstract:Abstract Background Increasing evidence suggests that hepatitis C virus (HCV) infection is associated with non-Hodgkin’s lymphoma (NHL). However, no clear consensus has been reached about the clinical features and effective treatment of HCV-associated NHL patients. We therefore performed a systematic review and meta-analysis to explore the clinical characteristics and effectiveness of antiviral treatment or rituximab administration among NHL patients with HCV infection. Methods Eight electronic databases, including PubMed, OVID, EMBASE, Cochrane Library, ClinicalTrials, WANFANG, CNKI, and VIP, were searched for eligible studies up to July 31, 2021. The hazard ratio (HR) or odds ratio (OR) corresponding to the 95% confidence interval (CI) was calculated to estimate the outcomes. Publication bias was assessed by Egger’s and Begg’s tests. Statistical analysis was performed with RevMan 5.4 software and Stata version 15. Results There were 27 shortlisted articles out of a total of 13,368 NHL patients included in the current meta-analysis. Our results demonstrated that NHL patients with HCV infection had a significantly shorter overall survival (OS: HR 1.89; 95% CI 1.42–2.51, P < 0.0001) and progression-free survival (PFS: HR 1.58; 95% CI 1.26–1.98, P < 0.0001), a lower overall response rate (ORR: OR 0.58, 95% CI 0.46–0.73, P < 0.00001) and a higher incidence of hepatic dysfunction during chemotherapy (OR 5.96; 95% CI 2.61–13.62, P < 0.0001) than NHL patients without HCV infection. HCV-positive NHL patients exhibited an advanced disease stage, an elevated level of LDH, a high-intermediate and high IPI/FLIPI risk as well as a higher incidence of spleen and liver involvement. Moreover, antiviral treatment prolonged survival (OS: HR 0.38; 95% CI 0.24–0.60, P < 0.0001), reduced disease progression [PFS/DFS (disease-free survival): HR 0.63; 95% CI 0.46–0.86, P = 0.003] and reinforced the treatment response (ORR: OR 2.62; 95% CI 1.34–5.11, P = 0.005) among the HCV-infected NHL patients. Finally, rituximab administration was associated with a favourable OS, while liver cirrhosis and low levels of albumin predicted a poor OS for HCV-positive NHL patients. Conclusions The current study provided compelling evidence about an inferior prognosis and distinct clinical characteristics among HCV-associated NHL patients. Antiviral treatment and rituximab-containing regimens were shown to be efficacious in improving the clinical outcomes of NHL patients with HCV infection.

Clinical analysis of fatty liver caused by non-Hodgkin lymphoma chemotherapy

Clinical Analysis of Hemopathy Patients with HBV Infection

Clinical Study of Fatty Livers in 37 Patients with Ovarian Cancer after Chemotherapy

Significance of Clinical Factors As Prognostic Indicators for Mature T-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis of Chinese Cases

New Utility of an Old Marker: Serum Low-Density Lipoprotein Predicts Histopathological Response of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.

Persistent Lymphopenia after Chemotherapy And/or Radiotherapy Predicted Unfavorable Outcome in Breast Cancer Patients - a Retrospective Cohort Study

[Clinical Analysis of Liver Non-Hodgkin's Lymphoma].

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Study on Chemotherapy-induced Disorders of Lipid Metabolism in Patients with Gynecologic Malignant Tumor

Efficacy and Safety Evaluation of Fludarabine-Based Chemotherapy Regimen for Patients with Non-Hodgkin Lymphoma A Meta-Analysis

Study on the Relationship between Phospholipids and Nonalcoholic Fatty Liver Disease

Relationship Between Non-Alcoholic Fatty Liver Disease and the Perioperative and Short-Term Prognosis of Breast Cancer

Association of the Frequency of Peripheral Natural Killer T Cells with Nonalcoholic Fatty Liver Disease

Need for intraoperative measurement of corneal thickness during LASIK.

Clinical Analysis of Liver Damage of Malignant Lymphoma Patients with Positive HBV Surface Antigen(hbsag)after Rituximab and Chemotherapy

The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients with Early-stage Breast Cancer

Analysis on the Change of Peripheral Blood T Lymphocyte Subsets Before and after Chemotherapy in Patients with Non-Small Cell Lung Cancer

Clinicopathological analysis of non-alcoholic steatohepatitis

Percutaneous Liver Biopsy: Retrospective Study of Primary and Secondary Hepatic Lymphoma in Twenty-One Patients

Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin’s lymphoma: a systematic review and meta-analysis

Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer